1.7006

0.29% -0.0194

Ventyx Biosciences Inc (VTYX)

Overview News Price History Option Chain Financials Why VTYX Down? Discussions Forecast

Ventyx Biosciences Inc stock is traded at $1.7006, with a volume of 200.79K. It is down -0.29% in the last 24 hours and down -28.24% over the past month. Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Previous Close:

$1.72

Open:

$1.73

24h Volume:

200.79K

Relative Volume:

0.17

Market Cap:

$123.39M

Revenue:

Net Income/Loss:

$-192.96M

P/E Ratio:

-0.6074

EPS:

-2.8

Net Cash Flow:

$-167.04M

1W Performance:

-12.94%

1M Performance:

-28.24%

6M Performance:

-63.82%

1Y Performance:

-26.39%

1-Day Range:

$1.70

$1.77

1-Week Range:

$1.70

$2.00

52-Week Range:

$1.70

$11.48

Ventyx Biosciences Inc Stock (VTYX) Company Profile

Name

Ventyx Biosciences Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

(858) 945-2393

Address

12790 EL CAMINO REAL, SUITE 200, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

VTYX's Discussions on Twitter

Compare VTYX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VTYX	1.705	123.39M	0	-192.96M	-167.04M	-2.80
VRTX	446.42	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	739.53	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	587.24	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.48	24.49B	3.30B	-501.07M	1.03B	11.54

Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-14-23	Resumed	Credit Suisse	Outperform
Mar-21-23	Initiated	Wells Fargo	Overweight
Dec-19-22	Initiated	Goldman	Buy
Nov-17-22	Initiated	Morgan Stanley	Overweight
Sep-07-22	Initiated	Stifel	Buy
Sep-01-22	Initiated	H.C. Wainwright	Buy
May-09-22	Initiated	Credit Suisse	Outperform
Mar-31-22	Initiated	Canaccord Genuity	Buy
Feb-01-22	Initiated	Oppenheimer	Outperform
Nov-15-21	Initiated	Jefferies	Buy
Nov-15-21	Initiated	Piper Sandler	Overweight

View All

Ventyx Biosciences Inc Stock (VTYX) Latest News

Nov 20, 2024

Thinking about buying stock in Solid Power, Crowdstrike Holdings - GuruFocus.com

Nov 20, 2024

Nov 19, 2024

Ventyx Biosciences stock hits 52-week low at $1.78 amid market shifts - Investing.com Australia

Nov 19, 2024

Nov 17, 2024

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance

Nov 17, 2024

Nov 14, 2024

We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully - Simply Wall St

Nov 14, 2024

Nov 12, 2024

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress - Yahoo Finance

Nov 12, 2024

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - The Manila Times

Nov 12, 2024

Nov 11, 2024

Ventyx Biosciences (NASDAQ:VTYX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024

Ventyx Biosciences’ (VTYX) “Outperform” Rating Reiterated at Oppenheimer - Defense World

Nov 11, 2024

Nov 08, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer - MarketBeat

Nov 08, 2024

Nov 07, 2024

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress - The Manila Times

Nov 07, 2024

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha

Nov 04, 2024

Nov 01, 2024

Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com

Nov 01, 2024

Oct 28, 2024

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider

Oct 28, 2024

Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat

Oct 28, 2024

Oct 17, 2024

HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat

Oct 17, 2024

Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com

Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com

Oct 16, 2024

Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK

Oct 16, 2024

Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire

Oct 16, 2024

Oct 15, 2024

Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat

Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com

Oct 15, 2024

Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada

Oct 15, 2024

VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Oct 15, 2024